- LINKS
-
More information
-
- Bookmark this page
- gross
Bayer: Novel cancer drug Regorafenib stops tumor growth at 81 percent of patients
Berlin, September 22, 2009
Dear visitor. This content is only available in German.
- Age-related macular degeneration (AMD)
- Breast cancer
- Central retinal vein occlusion (CRVO)
- Colorectal Cancer (CRC)
- Contraception
- Diabetes
- Diabetic macular edema (DME)
- Endometriosis
- Erectile dysfunction
- Gastrointestinal stromal tumor (GIST)
- Gynecological therapy
- Heart attack
- Heartattack and stroke
- Hemophilia
- High blood pressure
- Infectious diseases
- Liver cancer
- Lung cancer
- Menopausal complaints
- Multiple sclerosis
- Peripheral arterial occlusive disease
- Premenstrual dysphoric disorder (PMDD)
- Prostate cancer
- Pulmonary arterial hypertension
- Renalcell carcinoma
- Stroke
- Testosterone deficiency
- Thrombosis
- Thyroid Cancer
Page tools
- B/W version
- A | A | A | Font size
Clinical Trials
Information about clinical trials is available at
